Lisata Therapeutics Inc. has achieved a significant milestone in its ongoing Phase 1b/2a CENDIFOX trial by completing patient enrollment for the pancreatic cancer cohorts. CEO David Mazzo discussed the development with Proactive's Stephen Gunnion, highlighting the importance of this advancement in the fight against pancreatic cancer.
The trial, led by Dr. Anup Kasi at The University of Kansas Cancer Center, is designed to evaluate the safety and efficacy of certepetide, formerly known as LSTA1, in combination with FOLFIRINOX-based therapies. This combination therapy is being tested not only for pancreatic cancer but also for colon and appendiceal cancers.
A notable aspect of the trial is its capacity to collect pre- and post-treatment biopsies of tumors, providing valuable data on the treatment's impact. Mazzo also mentioned that efforts are ongoing to complete enrollment in two additional cohorts focusing on colorectal cancer and other tumor types, with expectations to finalize by the end of the year.
Expressing optimism, Mazzo noted the trial's encouraging progress and the enthusiasm it has generated among patients, particularly from the Kansas City area, despite competition from other studies. He anticipates preliminary results to be available by the end of the year, contingent on the timely processing of biopsies by external laboratories.
The completion of patient enrollment marks a crucial step forward in evaluating a potentially effective treatment for pancreatic cancer, a disease known for its poor prognosis and limited treatment options. The outcomes of this trial could have significant implications for cancer treatment protocols and offer new hope for patients battling these aggressive cancers.
